Close Menu
  • Home
  • Finance News
  • Personal Finance
  • Investing
  • Cards
    • Credit Cards
    • Debit
  • Insurance
  • Loans
  • Mortgage
  • More
    • Save Money
    • Banking
    • Taxes
    • Crime
What's Hot

Podcast 97: Money, Marriage, & Raising Financially Fit Kids with Andy Hill

July 10, 2025

The American dream gap: Why more men than women feel optimistic in today’s economy

July 10, 2025

Car Shopping? The ‘Big, Beautiful Bill’ May Change What You Pay

July 10, 2025
Facebook X (Twitter) Instagram
Facebook X (Twitter) Instagram
Smart SpendingSmart Spending
Subscribe
  • Home
  • Finance News
  • Personal Finance
  • Investing
  • Cards
    • Credit Cards
    • Debit
  • Insurance
  • Loans
  • Mortgage
  • More
    • Save Money
    • Banking
    • Taxes
    • Crime
Smart SpendingSmart Spending
Home»Financial Crime»AstraZeneca is reviewing the management of its scandal-hit Chinese division
Financial Crime

AstraZeneca is reviewing the management of its scandal-hit Chinese division

January 17, 2025No Comments3 Mins Read
Facebook Twitter LinkedIn Telegram Pinterest Tumblr Reddit WhatsApp Email
AstraZeneca is reviewing the management of its scandal-hit Chinese division
Share
Facebook Twitter LinkedIn Pinterest Email

Unlock the Editor’s Digest for free

AstraZeneca has overhauled its local management in China in a bid to put recent scandals behind it and revive sales following the arrest of the country’s president.

The FTSE 100 group has appointed new executives to lead its Chinese oncology business, which has come under heavy scrutiny following two incidents including alleged illegal sales practices for cancer drugs.

The scandal ensnared Chinese President Leon Wang, whom the company announced in November had been arrested, along with several other employees. AstraZeneca has lost more than £15 billion in market capitalization following reports of an investigation by local authorities.

Alex Lin will replace Michael Lai as the country’s chief executive, two people with direct knowledge of the matter said. Lai was one of Wang’s senior managers. Lai has moved to the US to take charge of a key cancer drug for AstraZeneca and report to the head of oncology, people close to the company said. Lai did not respond to a request for comment.

The drugmaker has promoted Mary Guan, who previously worked at China’s general medicine unit, to head of oncology in China as part of an effort to deal with the unit, a person familiar with the matter said.

AstraZeneca declined to comment. It has previously said it would cooperate fully with Chinese authorities, and also said Wang was cooperating with the investigation.

The drugmaker – the largest foreign pharmaceutical group in China by 2023 sales – is trying to restart its operations in China, where insiders say they expect a drop in sales as hospitals are unwilling to do business with the company. The new management will be crucial in putting AstraZeneca back on track in what was once its key growth market. China will contribute 13 percent of global sales in 2023.

See also  Home Warranty Division Scam: What to Know

The company wants to “show that there is a clear break with the old management,” said a person familiar with the company’s position.

Another person said that “many changes are expected in the China Leadership team, but have not yet been announced.”

AstraZeneca's Chinese operations have grown enormously under Wang

AstraZeneca CEO Iskra Reic was appointed in early December to take over from Wang, who also led the international region that includes other emerging markets.

“AstraZeneca has distanced itself from Leon and the other affected employees,” said a person close to the company.

They added that Wang was “under intense pressure to rejuvenate growth” after China’s revenues fell in 2022.

AstraZeneca executives have not received a formal explanation from Chinese authorities and have been unable to contact Wang, people familiar with the matter said. The company has concluded that the investigation concerns the alleged illegal import of the cancer drug Imjudo via Hong Kong into China – where the drug is not approved – because authorities have also arrested AstraZeneca’s former head of oncology, Yin Min arrested, who was in charge of the department. during the alleged crimes.

In addition, dozens of sellers have been convicted of health insurance fraud in the past two years after courts found they tampered with genetic test results to ensure lung cancer patients qualified for their drug Tagrisso under a national reimbursement system.

The drugmaker is pinning much of its hopes in China on its breast cancer drug Enhertu, which authorities recently said would be included in the state health insurance system.

Source link

AstraZeneca Chinese division Management reviewing scandalhit
Share. Facebook Twitter Pinterest LinkedIn Tumblr Telegram Email
Previous ArticleWhy now is an ideal time to do a financial reset, advisor says
Next Article Immigration Policy and the Economic Contributions of Latino Immigrants

Related Posts

EU to remove the VAE and Gibraltar from money laundering of the ‘gray’ list of money

July 9, 2025

French police raid from the extreme right-wing rassemblement National of Marine Le Pen

July 9, 2025

Assets Under Management (AUM): What It Is, How It’s Used

July 7, 2025
Add A Comment
Leave A Reply Cancel Reply

Top Posts

“Big, Beautiful Bill” Nearly Burns The Tanning Tax

May 24, 2025

Why buying a car in winter is a smart move

December 13, 2024

Your Retirement Emergency Fund: Why Emergency Savings Are the Foundation of Financial Wellness

June 8, 2025
Ads Banner

Subscribe to Updates

Subscribe to Get the Latest Financial Tips and Insights Delivered to Your Inbox!

Stay informed with our finance blog! Get expert insights, money management tips, investment strategies, and the latest financial news to help you make smart financial decisions.

We're social. Connect with us:

Facebook X (Twitter) Instagram YouTube
Top Insights

Podcast 97: Money, Marriage, & Raising Financially Fit Kids with Andy Hill

July 10, 2025

The American dream gap: Why more men than women feel optimistic in today’s economy

July 10, 2025

Car Shopping? The ‘Big, Beautiful Bill’ May Change What You Pay

July 10, 2025
Get Informed

Subscribe to Updates

Subscribe to Get the Latest Financial Tips and Insights Delivered to Your Inbox!

© 2025 Smartspending.ai - All rights reserved.
  • Contact
  • Privacy Policy
  • Terms & Conditions

Type above and press Enter to search. Press Esc to cancel.